Crossmark

Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry

Crossref DOI link: https://doi.org/10.1186/s13075-024-03287-9

Published Online: 2024-02-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Calvo-Gutiérrez, Jerusalem http://orcid.org/0000-0001-6822-5589
López-Medina, Clementina http://orcid.org/0000-0002-2309-5837
Otero-Varela, Lucía http://orcid.org/0000-0002-4406-6314
Escudero-Contreras, Alejandro

Ortega-Castro, Rafaela http://orcid.org/0000-0002-7552-3469
Ladehesa-Pineda, Lourdes

Campos, Cristina

Bernabeu-Gonzalvez, Pilar

Pérez-Gómez, Ana

García-Dorta, Alicia

Ruiz-Montesino, Dolores

Pombo-Suarez, Manuel

Ros-Vilamajo, Inmaculada http://orcid.org/0000-0002-5819-6451
Sánchez-Alonso, Fernando

Castrejón, Isabel http://orcid.org/0000-0003-1811-2417
License Information

Text and Data Mining valid from 2024-02-23

Version of Record valid from 2024-02-23
More Information

Article History

Received: 29 October 2023

Accepted: 13 February 2024

First Online: 23 February 2024

Declarations

:

: The project was approved by the Ethics Review Committee of the Hospital Universitario Clinic Barcelona (approval code FER-ADA-2015-01), although the Hospital de Canarias Ethics Committee is currently acting as the reference committee. Informed consent was obtained from all participants.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below